Modelled Public Health Impact of Introducing Adjuvanted Recombinant Zoster Vaccine into the UK National Immunisation Programme

Modelled Public Health Impact of Introducing Adjuvanted Recombinant Zoster Vaccine into the UK National Immunisation Programme

Abstract Introduction In 2023, recombinant zoster vaccine (RZV) replaced zoster vaccine live (ZVL) vaccine in the UK National Immunisation Programme (NIP) for prevention of herpes zoster (HZ). The vaccination age was reduced from 70 to 65 years, with a subsequent planned reduction to 60 years. This...

Full description

Saved in:
Bibliographic Details
Main Authors: Manjit Hunjan, Desmond Curran, Alen Marijam, Yasmeeta Vekria, Nikolaos Giannelos
Format: Article
Language:English
Published: Adis, Springer Healthcare 2024-11-01
Series:Infectious Diseases and Therapy
Subjects:
Herpes zoster
Post-herpetic neuralgia
Vaccination
Recombinant zoster vaccine
Zoster vaccine live
Healthcare burden
Online Access:https://doi.org/10.1007/s40121-024-01073-3
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1007/s40121-024-01073-3

Similar Items